Hormone replacement therapy and cardiovascular disease: influence of oestrogen replacement therapy on chest pain

	Prospectively registered
No longer recruiting	☐ Protocol
Overall study status	Statistical analysis plan
Completed	Results
Condition category	Individual participant data
Circulatory System	Record updated in last year
	Completed Condition category

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr J McLenachan

Contact details

Leeds General Infirmary
Department of Cardiology
Great George Street
Leeds
United Kingdom
LS1 3EX
+44 (0)113 2926476
Jim.McLenachan@leedsth.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Hormone replacement therapy and cardiovascular disease: influence of oestrogen replacement therapy on chest pain

Study objectives

Angina in post-menopausal women is a common clinical problem that is often underinvestigated and under-treated. While most women with angina have atherosclerotic coronary disease, many have angina with anatomically normal coronary arteries (so-called Syndrome X). Those women with angina and coronary artery disease have a high risk of major cardiovascular events including unstable angina, myocardial infarction and death. Indeed, recent evidence suggests that while coronary disease is declining in men, the incidence of major events continues to rise in women, and may equal that of men in less than two decades. Women with angiographically normal coronary arteries present a different problem; although they have a good prognosis, their symptoms do not respond well to conventional anti-angina therapy and their morbidity and hospital re-admission rate is high. Hormone replacement therapy (HRT) with oestrogen reduces the incidence of cardiac events in post-menopausal women by up to 50%, by mechanisms that have not been elucidated. Interest has recently focused on the functions of the innermost layer of the coronary artery, the coronary endothelium. In health, the endothelial cells cause the artery to dilate in response to a number of physical and chemical stimuli. This function, called endothelium-dependant vasodilation, is lost in the early phase of coronary atherosclerosis and may precipitate further vascular damage. In animal models, HRT given to oophorectomised females can restore normal endothelial function, and may retard the development of atherosclerosis. An analogous abnormality in the endothelial control of coronary blood flow has been identified in Syndrome X. In neither case has the effect of HRT on coronary artery responsiveness been studied in humans. Nor has there been investigation of the effect of HRT on symptoms (i.e. chest pain, exercise tolerance) in either women with or without coronary disease. We plan to assess the influence of HRT on coronary artery responses in postmenopausal women with angina, both with and without coronary artery disease, in an unblinded single angiographic study. Ischaemic heart disease accounts for 24% of all deaths in women aged between 55-74, being the largest single cause of death in this group. The potential benefit to the nation, in both health and financial terms, of more effective therapy and prevention of this burden of disease is great. This study aims to examine mechanisms by which HRT might prevent death and other major cardiovascular events, as well as exploring for the first time the therapeutic potential of HRT in the treatment of chest pain in with and without coronary artery disease. The information acquired may provide the basis for larger controlled trials of HRT as symptomatic and preventative therapy for heart disease in post-menopausal women.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Cardiovascular diseases: heart disease

Interventions

Not provided at time of registration

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

08/01/1994

Completion date

30/09/1996

Eligibility

Key inclusion criteria

Post-menopausal women with angina

Participant type(s)

Patient

Age group

Not Specified

Sex

Female

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

08/01/1994

Date of final enrolment

30/09/1996

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Leeds General Infirmary

Leeds United Kingdom LS1 3EX

Sponsor information

Organisation

NHS R&D Regional Programme Register - Department of Health (UK)

Sponsor details

The Department of Health Richmond House 79 Whitehall London United Kingdom SW1A 2NL +44 (0)20 7307 2622 dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

http://www.doh.gov.uk

Funder(s)

Funder type

Government

Funder Name

NHS Executive Northern and Yorkshire (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration